Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Voyageur Pharmaceuticals Ltd V.VM

Alternate Symbol(s):  VYYRF

Voyageur Pharmaceuticals Ltd. is a Canada-based company engaged in the development of barium and iodine Active Pharmaceutical Ingredients (API) and offers high-performance imaging contrast agents. The Company is focused on vertically integrating the barium and iodine contrast market, and aims at producing its own barium, iodine, and endo fullerenes. The Company’s products include SmoothX, SmoothHD, SmoothLD, VisionHD, VisionLD and V-Gas. SmoothX (2%w/v) is a contrast medium for use in computed tomography (CT) of the gastrointestinal tract. VisionHD is a high-density (98% w/w) barium powder suspension tailored for double-contrast radiographic examination of the gastrointestinal tract, esophagus, stomach and duodenum. It also owns a 100% interest in the Frances Creek barium sulfate (barite) project, which is a rare grade mineral suitable for the pharmaceutical marketplace that is intended to replace the current synthetic products with quality imaging products.


TSXV:VM - Post by User

Comment by WarrantOfficeron Jun 05, 2021 1:46pm
245 Views
Post# 33336193

RE:ASTONISHING

RE:ASTONISHINGThey were planning for a total of 1.5M, they now have that. Combined with the 1.3M they have raised prior, Voyageur is well postioned to advance their strategic planning into production. It may be in their best interests to cease their capital raising now. Summer months have been historically hum drum for the market. This could dip down to a dime.

I do expect plenty of good news in 4th quarter this year. FDA approval will send this stock significantly higher. To many people worried about  pennies when this stock is headed into the dollars if management can execute their strategic planning. Outside of China, this is the only medical grade barium sulphate mine in the world. Further, I do not trust anything made in China as there is well documented cases of ingredient fraud, safety standards violations and government cohersion. Voyageur will quickly be the "go to' barium sulphate company in the medical community. 

Value added with their two industrial barium sulphate mines and advancing their iodine plans will triple their revenue.I believe long holders will be greatly rewarded. 
<< Previous
Bullboard Posts
Next >>